

## **BELGRAVIA CAPITAL adds to expertise in corporate development and expands medical advisory committee**

---

TORONTO, March 12, 2018 - (GLOBE NEWSWIRE) - BELGRAVIA CAPITAL INTERNATIONAL INC. (CSE:BLGV) (OTCQB:BLGVF) (“Belgravia Capital”, “Belgravia”, or the “Company”) is pleased to announce senior additions to its management team. Dr. Shoaib Sheikh, is joining as medical advisor, and Mr. Jason Batista is joining as Director of Corporate Development.

Dr. Shoaib Sheikh is joining the medical advisory committee of Belgravia. Dr. Sheikh, a physician, is an accomplished laparoscopic surgeon and the Chair of the Technology Committee of the American Association of Hand Surgeons. He has also studied the management of health care delivery and high performance healthcare leadership at Harvard Business School.

Mr. Mehdi Azodi, President and Chief Executive Officer of the Company stated: “Dr. Sheikh’s leadership skills will enhance our ability to execute in planned commercial developments in the Cannabidiol (“CBD”) space. We are carefully advancing opportunities in this space. Dr. Sheikh is joining Dr. Sam Hanna on the medical advisory committee. Dr. Hanna, a recognized Canadian dermatologist, is assisting the Company in its development of opportunities in the Cannabidiol commercial space. We plan to shortly provide details regarding Belgravia-financed and Belgravia-led dermatological product developments in both the cosmetic and medicinal areas of this space.”

The Company is also pleased to announce that Mr. Jason Batista has also joined Belgravia as Director of Corporate Development. His education includes financial management and advanced courses in financial planning. Since 2002 he has worked as an investment advisor for two Canadian bank owned investment dealers. He will be working with Mr. Mehdi Azodi, the President and Chief Executive Officer of the Company, in reviewing and managing the investment portfolio.

As described in the Company’s press release of October 17, 2017, the Company, through a royalty streaming division, holds an interest in anticipated water royalties, which may be earned from the sales of water rights in the state of New Mexico. Belgravia expects to provide specific terms regarding the water royalties by the third quarter of 2018.

Belgravia’s business model includes actively developing commercial opportunities in the legal cannabis space such as taking CBD concepts through to medical products, making shorter term investments in the legal medical cannabis space, and making investments in other spaces unrelated to cannabis, but on an opportunistic basis. Water royalty revenues would fall into the later model of value creation for Belgravia shareholders.

## **About Belgravia Capital**

Belgravia Capital International is focused on the provision of value-added services to the international legal Cannabis industry. The strategy is based on investing in international licit cannabis growth companies on a selective basis, and supporting the genesis and development of novel products and marketing concepts in the Cannabis space. Software developments include quality product attestation and loyalty program platforms. Investments will include developing licensed producers and distributors and product developers.

Belgravia Capital intends to establish joint research and development partnerships with Licensed Producers operating under ACMPR regulations in Canada and in other jurisdictions where medicinal cannabis is fully legal. Belgravia Capital may invest in various private and public companies in other industry sectors on an opportunistic basis. For more information, please visit [www.belgraviacapital.ca](http://www.belgraviacapital.ca).

## **Forward-Looking Statements**

Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements include statements that use forward-looking terminology such as “may”, “will”, “expect”, “anticipate”, “believe”, “continue”, “potential” or the negative thereof or other variations thereof or comparable terminology. Such forward-looking statements include, without limitation, statements regarding planned investment activities & related returns, trends in the markets for fertilizers and medicinal or recreational use of cannabis, the timing or assurance of the legalization of recreational cannabis, the timing for completion of research and development activities, the potential value of royalties from water and other resources, and other statements that are not historical facts. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of the Company, including, but not limited to, changes in market trends, the completion, results and timing of research undertaken by the Company, risks associated with resource assets, the impact of general economic conditions, commodity prices, industry conditions, dependence upon regulatory, environmental, and governmental approvals, the uncertainty of obtaining additional financing, and risks associated with cannabis use for medicinal or recreational purposes. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements.

## **For More Information, Please Contact:**

Mehdi Azodi, President & CEO

Belgravia Capital

(416) 779-3268

[mazodi@blgv.ca](mailto:mazodi@blgv.ca)

